Company Overview and News
Stop missing out on important events!
SUDA (ASX:SUD) has signed an agreement with UK-based Aluztra Bio to acquire the global intellectual property relating to a novel anti-cancer agent, Anagrelide.
Suda (ASX:SUD) has been granted a trading halt by the ASX this morning, with its shares placed in pre-open.
SUDA (ASX:SUD) has submitted the marketing authorisation application (MAA) for its ArTiMist® spray to the Australian Therapeutic Goods Administration (TGA).